doi: 10.1126/science.1241159.
Antimitotic activity of the potent tumor inhibitor maytansine
- PMID: 1241159
- DOI: 10.1126/science.1241159
Item in Clipboard
Antimitotic activity of the potent tumor inhibitor maytansine
Science.
.
Abstract
Maytansine, at 6x10(-8)M, irreversibly inhibits cell division in eggs of sea urchins and clams. It causes the disappearance of a mitotic apparatus or prevents one from forming if added at early stages. Maytansine does not affect formation of the mitotic organizing center but does inhibit in vitro polymerization of tubulin. Maytansine and vincristine inhibit in vitro polymerization of tubulin at about the same concentrations, but vincristine is about 100 times less effective as an inhibitor of cleavage in marine eggs.
Similar articles
-
Antimitotic and antitubulin activity of the tumor inhibitor steganacin.Cancer Res. 1977 Sep;37(9):3071-9. Cancer Res. 1977. PMID: 560248
-
Regulation of the in vivo mitotic apparatus by glycols and metabolic inhibitors.Ann N Y Acad Sci. 1975 Jun 30;253:362-77. doi: 10.1111/j.1749-6632.1975.tb19214.x. Ann N Y Acad Sci. 1975. PMID: 1096720 Review. No abstract available.
-
Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids.J Med Chem. 1978 Jan;21(1):31-7. doi: 10.1021/jm00199a006. J Med Chem. 1978. PMID: 563462
-
Effects of new antimitotic antibiotics, ansamitocins, on the growth of murine tumors in vivo and on the assembly of microtubules in vitro.Cancer Res. 1980 May;40(5):1707-17. Cancer Res. 1980. PMID: 6245801 No abstract available.
-
Recent developments in tubulin polymerization inhibitors: An overview.Eur J Med Chem. 2014 Nov 24;87:89-124. doi: 10.1016/j.ejmech.2014.09.051. Epub 2014 Sep 16. Eur J Med Chem. 2014. PMID: 25240869 Review.
Cited by
-
The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.Clin Cancer Res. 2013 Apr 1;19(7):1795-805. doi: 10.1158/1078-0432.CCR-12-3613. Epub 2013 Feb 20. Clin Cancer Res. 2013. PMID: 23426279 Free PMC article. Clinical Trial.
-
Progress in Gynecologic Cancers with Antibody Drug Conjugates.Curr Oncol Rep. 2021 Jun 14;23(8):89. doi: 10.1007/s11912-021-01080-4. Curr Oncol Rep. 2021. PMID: 34125311 Review.
-
Increased yield of AP-3 by inactivation of asm25 in Actinosynnema pretiosum ssp. auranticum ATCC 31565.PLoS One. 2022 Mar 22;17(3):e0265517. doi: 10.1371/journal.pone.0265517. eCollection 2022. PLoS One. 2022. PMID: 35316825 Free PMC article.
-
Development and Characterization of a Novel Peptide-Drug Conjugate with DM1 for Treatment of FGFR2-Positive Tumors.Biomedicines. 2021 Jul 21;9(8):849. doi: 10.3390/biomedicines9080849. Biomedicines. 2021. PMID: 34440055 Free PMC article.
-
Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.Molecules. 2017 Aug 1;22(8):1281. doi: 10.3390/molecules22081281. Molecules. 2017. PMID: 28763044 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
